Healthcare
Live Price
Offline$405.55
-0.47% today
1Y Change
+34.28%
Window
Jun 20, 2025 → Jun 11, 2026
Coverage: 245 bars · Jun 20, 2025 → Jun 11, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
UnitedHealth Group Incorporated (UNH) is a Healthcare stock with a market cap of $334.73B and listed on NYSE. The stock last traded around $405.55 and up 34.3% across the available one-year price window (Jun 20, 2025 → Jun 11, 2026). Baseline metrics include revenue growth of +11.8%, EPS growth of -15.4%, a dividend yield of 2.4%. What stands out right now is revenue +11.8%, EPS -15.4%, free cash flow -22.4% with operating margin 4.2% and ROIC 8.1%. The dividend is present but secondary, with a yield around 2.4%. Valuation is more restrained than many high-expectation growth names at P/E 27.9 and price/sales 0.7. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines UNH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
UNH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
UNH Max Drawdown
-29.98%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for UNH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$287.6B
-11.3% YoY
FY Net Income
$17.3B
-14.1% YoY
Free Cash Flow
$19.9B
-15.0% YoY
Revenue Growth
+11.8%
EPS Growth
-15.4%
Gross Margin
18.8%
Net Margin
2.7%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 447.6B | 400.3B | 371.6B | 324.2B | 287.6B |
| Gross Profit | 82.9B | 89.4B | 91.0B | 79.6B | 69.7B |
| Operating Income | 19.0B | 32.3B | 32.4B | 28.4B | 24.0B |
| EBITDA | 23.1B | 28.1B | 36.3B | 31.8B | 27.1B |
| Net Income | 12.1B | 14.4B | 22.4B | 20.1B | 17.3B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 24.4B | 25.3B | 25.4B | 23.4B | 21.4B |
| Total Assets | 309.6B | 298.3B | 273.7B | 245.7B | 212.2B |
| Total Liabilities | 207.9B | 195.7B | 174.8B | 159.4B | 135.7B |
| Shareholder Equity | 94.1B | 92.7B | 88.8B | 77.8B | 71.8B |
| Total Debt | 78.4B | 76.9B | 67.4B | 57.6B | 46.0B |
| Net Debt | 54.0B | 51.6B | 42.0B | 34.3B | 24.6B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
22.3B
-14.7% YoY
Capital Expenditures
2.5B
+12.4% YoY
Free Cash Flow
19.9B
-15.0% YoY
Key ratios
Gross Margin
18.8%
Operating Margin
4.2%
Net Margin
2.7%
ROE
12.4%
Debt / Equity
0.75x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.